News

Approximately 24 healthy postmenopausal women have been enrolled in the study, which is designed to assess product safety and measure parathyroid hormone (PTH) blood levels at varying doses.

There were no new or unexpected safety signals reported in the study. An independent review of the primary endpoint is being conducted for US regulatory purposes. REACH is

While there was a trend in favor of Synavive, and an observed dose-response relationship, the combination did not demonstrate statistical significance compared to placebo for WOMAC question #1

Dr Smith will be responsible for all investor relations functions and will report directly to CFO, Kurt Leutzinger. Most recently, Dr Smith was a vice president and senior

MedX’s distribution partner, Technology4Medicine, a laser company in San Clemente, California will begin immediate distribution of Oralase to dental offices in the US. Oralase is a photobiomodulation device,

In addition, preliminary analysis of blinded data from nearly 4,000 patients participating in a series of four ongoing Phase III trials supports that the naltrexone sustained release (SR)

Joseph Papa, chairman and CEO of Perrigo, said: “The acquisition of Laboratorios Diba will enable us to market an additional 150 formulas and 50 trademarks into the rapidly

Under the terms of the asset acquisition agreement, the company will pay an aggregate cash consideration of $345 million in installments with the final payment to be made

The results from the Phase II prospective randomized placebo-controlled study of 125 patients with advanced prostate cancer after four years of follow-up show that patients receiving Prostvac had